Backlight Names Benjamin Desbois as Chief Operating Officer
1.8.2023 13:30:00 EEST | Business Wire | Press release
Global media and entertainment technology company Backlight today announced the appointment of Benjamin Desbois to chief operating officer (COO) of Backlight. Desbois joins Backlight from Telestream, a leading provider of solutions for media creation and production, where he had served as chief revenue officer since 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230801619740/en/
Global media and entertainment technology company Backlight today announced the appointment of Benjamin Desbois to chief operating officer (COO) of Backlight. (Photo: Business Wire)
“Benjamin is a media and entertainment industry veteran with proven success driving growth and scaling customer-facing functions including sales, sales engineering, professional services, and customer success,” said president and CEO of Backlight, Ben Kaplan. “This track record, combined with Benjamin’s deep experience working with strategic customers and partners, global teams and supporting M&A integration, makes him a terrific addition to the Backlight team.”
Benjamin Desbois brings more than 20 years of experience in media and entertainment technology and has a deep understanding of media workflows and customer needs. Prior to Telestream, he held several management positions at Avid Technology, most recently as vice president of sales for the Americas. Before Avid, Benjamin was general manager for North America at Dalet. Earlier in his career at Dalet, he held a range of product management, professional services and sales positions.
As a senior leader, Benjamin has become known for his collaborative and team-oriented leadership style and working effectively with executive teams on strategy, innovation, operational excellence, integration, HR and culture. His deep industry experience includes helping to acquire and integrate numerous media technology products and teams.
“Backlight’s compelling thesis and the momentum the company has built thus far is exciting,” said Benjamin Desbois. “I look forward to working with the talented Backlight team to expand our reach, accelerate growth and deliver incredible innovative solutions that help our customers maximize value in their respective fields.”
Benjamin is a graduate of L’Ecole Des Mines De Paris and resides in Miami, Florida.
About Backlight
Backlight is a global media technology company that dramatically improves every stage of the video and entertainment content lifecycle – from creation through monetization. Backed by $200M in funding from PSG, Backlight has acquired six leading media software companies since launching in 2021. Video-forward organizations solve their mission-critical business and operational challenges by partnering with Backlight’s two divisions: Backlight Creative and Backlight Streaming. Backlight Creative provides award-winning software solutions for secure and efficient media management, production tracking and creative collaboration including iconik, ftrack, Gem and Celtx. Backlight Streaming provides cloud-based OTT video streaming, content management, media production, hyperdistribution, and monetization software, including Zype and Wildmoka, to world’s most innovative publishers and broadcasters. For more information visit backlight.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230801619740/en/
Contact information
Backlight Corporate Communications | media@backlight.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom